12:00 AM
May 14, 2012
 |  BC Week In Review  |  Company News  |  Deals

Fluidigm, Novartis deal

An option that would have granted Novartis' Novartis Vaccines & Diagnostics Inc. subsidiary sole rights to Fluidigm's PCR technology expired unexercised on April 30. The rights covered the use of the technology...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >